James J. Harding, MD

101 posts

James J. Harding, MD banner
James J. Harding, MD

James J. Harding, MD

@HardingJJMD

Medical Oncologist | Clinical Investigator | Cancer Drug Developer | Associate Chair IRB | HPB Cancers | Phase 1 | MSKCC

New York Katılım Haziran 2023
329 Takip Edilen606 Takipçiler
James J. Harding, MD retweetledi
Angela Lamarca
Angela Lamarca@DrAngelaLamarca·
An absolute honour @HardingJJMD 😊 🗞️Just published! Our latest review on #targeted therapies in #BiliaryMalignancies in @JHepatology sciencedirect.com/science/articl…
Angela Lamarca tweet mediaAngela Lamarca tweet mediaAngela Lamarca tweet mediaAngela Lamarca tweet media
James J. Harding, MD@HardingJJMD

@DrAngelaLamarca and Do Youn Oh! @HardingJJMD enjoyed writing with you on #personalized #therapy #biliarytractcancers. Promise, limitations, and solutions! @MSK_DeptOfMed @MSKCancerCenter @JHepatology sciencedirect.com/science/articl…

English
3
20
62
5.1K
James J. Harding, MD retweetledi
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center@MSKCancerCenter·
New findings presented at #ASCO26 suggest a new approach could help slow the growth of intermediate-stage liver cancer. An international phase 3 clinical trial led by MSK's Dr. Ghassan K. Abou-Alfa (@GABOUALFA) found that adding dual immunotherapy to TACE significantly increased progression-free survival for people with hepatocellular carcinoma (HCC). “By combining dual immunotherapy with TACE, we give patients a better chance of living longer while preserving a healthy, working liver.” Learn more: bit.ly/4x7vt7o
Memorial Sloan Kettering Cancer Center tweet media
English
0
9
15
1.6K
James J. Harding, MD retweetledi
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center@MSKCancerCenter·
Proud to see 18 MSK staff recognized as 2026 Conquer Cancer Grants & Awards recipients ahead of #ASCO26. Congratulations to this outstanding group helping advance the future of cancer research and care. 👏
Conquer Cancer, the ASCO Foundation@ConquerCancerFd

We're thrilled to officially announce the 2026 class of Conquer Cancer Grants and Awards recipients! 🔬 These grants empower the next generation of physician-scientists to turn innovative ideas into clinical breakthroughs. Congratulations to the new class—see you in Chicago for #ASCO26! Full list of recipients here: bit.ly/4x0qpBF #ResearchConquersCancer #ConquerCancer @ASCO

English
0
9
30
3.5K
James J. Harding, MD retweetledi
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center@MSKCancerCenter·
⚠️ New MSK research presented at #AACR26: A drug given “breakthrough designation” by @US_FDA may offer the best new option in many years for people facing #pancreaticcancer. #Daraxonrasib targets mutations in the RAS gene, which helps control cell growth — these mutations send signals that fuel cancer cells. #KRAS is the most common of these mutations and drives over 90% of pancreatic cancer, which is projected to be the second most deadly cancer in the U.S. by 2030. MSK gastrointestinal medical oncologist @EileenMOReilly led a phase 1/2 clinical trial of daraxonsarib as part of a larger multidisease trial led by thoracic medical oncologist Dr. @KCArbourMD. In Dr. O’Reilly’s trial, the patients with pancreatic cancer had not yet received any form of treatment. “This drug is potentially going to be a landmark shift in how we treat pancreatic cancer,” says Dr. O'Reilly. “The ability to target RAS mutations that drive so much of pancreatic cancer is huge and has been missing from our treatments.” Learn more about this research: bit.ly/4trr1xK @AACR
Memorial Sloan Kettering Cancer Center tweet media
English
1
36
158
13.5K
James J. Harding, MD retweetledi
Rohit Thummalapalli
Rohit Thummalapalli@rohit_thum·
Great to present phase 1b data for DLL3 ADC ZL-1310 (zoci) in platinum-refractory neuroendocrine carcinomas at #AACR26. Phase 2 is ongoing and we are excited to develop this drug further for these difficult to treat populations. @ZaiLab_Global @MSKCancerCenter @MSK_DeptOfMed
Rohit Thummalapalli tweet media
English
1
4
22
3.6K
James J. Harding, MD retweetledi
Arndt Vogel
Arndt Vogel@ArndtVogel·
🔥off the press: EMERALD-3 Phase III trial positive. 👉Significant PFS benefit for STRIDE/Lenva + TACE, trend of OS benefit 👉Trend for PFS benefit for STRIDE + TACE 🧐Looking forward to see more details @myESMO @EASLedu @ILCAnews
Arndt Vogel tweet media
English
0
30
66
3.7K
James J. Harding, MD retweetledi
Ghassan Abou-Alfa
Ghassan Abou-Alfa@GABOUALFA·
It was a great honor and delight for @MSKCancerCenter @MSK_DeptOfMed @GABOUALFA and @HardingJJMD to join this superb teaching effort. Thanks @oncodaily for the opportunity
OncoDaily@oncodaily

𝗛𝗼𝘄 𝗜 𝗧𝗿𝗲𝗮𝘁 𝗚𝗮𝗹𝗹𝗯𝗹𝗮𝗱𝗱𝗲𝗿 𝗮𝗻𝗱 𝗕𝗶𝗹𝗲 𝗗𝘂𝗰𝘁 𝗖𝗮𝗻𝗰𝗲𝗿 𝗶𝗻 𝟮𝟬𝟮𝟲 | 𝗢𝗻𝗰𝗼𝗗𝗮𝗶𝗹𝘆 𝗩𝗶𝗿𝘁𝘂𝗮𝗹 𝗦𝘂𝗺𝗺𝗶𝘁 The Gallbladder and Bile Duct Cancer Summit 2026, organized by OncoDaily, brought together international experts to examine evolving clinical strategies and innovation shaping the management of gallbladder and biliary tract cancers. During this session, Ghassan Abou-Alfa (@GABOUALFA), James J Harding (@HardingJJMD), Vinay Kumar Kapoor (@vkkapoor_india) and Thatcher Heumann (@HeumannThatcher) shared expert perspectives on contemporary systemic therapy for biliary tract cancers, the fundamental “Ten Commandments” guiding gallbladder cancer management, practical approaches to treating gallbladder cancer in clinical practice, and emerging HER2- and RAS-targeted therapies shaping the future of hepatobiliary oncology.💡 Join the live conversation: x.com/i/broadcasts/1… #OncologySummit #GlobalOncology #CancerTreatment #OncoDaily #Oncology #Cancer #Health #Medicine #GallbladderCancer

English
1
2
14
1.4K

Keşfet

@JHepatology @DrAngelaLamarca @MSK_DeptOfMed @MSKCancerCenter @CowzerDarren @MskccCMO @DSolit @GABOUALFA